Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold

Yamac, Aylin Hatice; Yıldız, Abdulkadir; Nasifov, Meherrem; Taştan, Ahmet; Bashirov, Nemat; Göktekín, Ömer

doi:10.5543/tkda.2016.21774

Cited by 5 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some smaller studies have assessed vessel/scaffold patency of BRS in CTO via imaging techniques. Similar to our study, a high rate of technical scaffold implantation success and low rate of cardiac events have been reported . However, these were (1) single‐center studies, (2) limited to mid‐term FU (i.e., MSCT at 6 months), and/or (3) based on invasive quantitative coronary angiography, which inherently carries a greater risk of complications.…”

Section: Discussionsupporting

confidence: 81%

“…The available reports currently focus on clinical outcomes, short-/ mid-term (noninvasive) follow-up (FU) (66 months) without (or limited) quantitative analyses, and/or invasive imaging strategies (i.e., quantitative angiography or optical coherence tomography) [9][10][11][12][13][14][15][16][17][18]. Therefore, this multicenter, prospective study aimed to assess the feasibility and safety of BRS when used for the interventional treatment of CTOs, by analyzing the outcomes and scaffold patency at one year, both clinically and via use of noninvasive multislice computed tomography (MSCT) imaging.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

One‐year clinical and computed tomography follow‐up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions

Maeremans

Verhaert

Pereira³

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

One‐year clinical and computed tomography follow‐up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions

Maeremans

Verhaert

Pereira³

et al. 2017

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Incidence of non-fatal myocardial infarction was 1.07% (95% CI: 0.09% to 2.06%). Incidence of target lesion revascularization was 2.51% (95% CI: 0.86% to 4.16%) with the highest rate of 8.6% reported by Yamac et al [16]. The incidence of probable or definite scaffold thrombosis was 1.3% (95% CI: -0.09% to 2.39%).…”

Section: Reviewmentioning

confidence: 97%

“…This group includes 11 publications among which the majority were small retrospective and prospective registries [6, 12-14, 16-19, 21-23]. Patient demographic and clinical characteristics were similar in all studies with similar reported outcomes (Table 3).…”

Section: Reviewmentioning

confidence: 99%

“…A composite of cardiac death, target vessel MI, and target lesion revascularization was reported for five out of 11 studies and was 2.64% (95% CI: 1.04% to 4.24%). Only one study, performed by Yamac et al, reported a single cardiac death (3% of their total population) during the follow-up period [16]. Maeremans et al were the only authors to report a non-cardiac death (2.4% of their study population) [14].…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Outcomes of Successful Revascularization of Chronic Total Coronary Occlusions with Bioresorbable Vascular Scaffolds: A Systematic Review

Marchenko

Nazir

Malla

et al. 2018

Cureus

View full text Add to dashboard Cite

Revascularization of chronic total occlusions (CTO) with percutaneous coronary intervention is associated with favorable long-term clinical and echocardiographic outcomes. Whether bioresorbable vascular scaffolds (BVS) would be advantageous in the treatment of CTO is unknown as patients with these lesions were generally excluded from large BVS randomized trials. We performed a systematic review, which sought to summarize known data on mid- to long-term clinical outcomes for BVS in CTO. We searched MEDLINE, EMBASE, clinicaltrials.gov, and the Cochrane Library through April 2018 to look for studies on implantation of BVS in CTO. Outcomes of interest included myocardial infarction, cardiac death, all-cause mortality, major adverse cardiac events (MACE), vessel restenosis, scaffold thrombosis, and target lesion revascularization. A total of 13 articles met the inclusion criteria for analysis. All studies were observational with a total number of patients of 1,077. Only two studies included comparator groups which retrospectively compared BVS with drug-eluting stents (DES). The studies had variable size (21 to 537) and follow-up duration (3–23 months). The review showed favorable outcomes for BVS implantation in CTO with the reported incidence of MACE ranged from 0% to 6.7% with no significant differences between BVS and DES groups in double arm studies. Although data on the use of first-generation BVS in CTO are sporadic and limited by small sample observational studies, available evidence is promising and suggests of acceptable outcomes comparable with second generation DES. Further investigation with randomized clinical trials and use of newer generation scaffolds is required.

show abstract

Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis

Polimeni

Anadol²,

Münzel³

et al. 2019

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundBRS represent a new approach to treating coronary artery disease. Beneficial properties of BRS regarding the restoration of vasomotility after resorption make them attractive devices in CTO revascularization. However, experience in this setting is limited.MethodsWe systematically searched Medline, Scholar, and Scopus for reports of at least 9 patients with CTO undergoing BRS implantation. Patients’ and procedural characteristics were summarized. The primary outcome of interest was target lesion revascularization (TLR). Pooled estimates were calculated using a random-effects meta-analysis. The study protocol was registered in PROSPERO (CRD42017069322).ResultsThirteen reports for a total of 843 lesions with a median follow-up of 12 months (IQR 6–12) were included in the analysis. At short-term, the summary estimate rate of TLR was 2.6% (95% CI: 1 to 4%, I2 = 0%, P = 0.887) while at mid to long-term it was 3.8% (95% CI: 2 to 6%, I2 = 0%, P = 0.803). At long-term follow-up (≥12 months), the summary estimate rate of cardiac death was 1.1% (95% CI: 0 to 2%, I2 = 0%, P = 0.887). The summary estimate rates of scaffold thrombosis and clinical restenosis were respectively 0.9% (95% CI: 0 to 2%, I2 = 0%, P = 0.919) and 1.8% (95% CI: 0 to 4%, I2 = 0%, P = 0.448). Finally, the summary estimate rate of target vessel revascularization was 6.6% (95% CI: 0 to 11%, I2 = 0%, P = 0.04).ConclusionsImplantation of BRS in a population with CTO is feasible, although further longer-term outcome studies are necessary.Electronic supplementary materialThe online version of this article (10.1186/s12872-019-1042-2) contains supplementary material, which is available to authorized users.

show abstract

Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold

Cited by 5 publications

References 0 publications

One‐year clinical and computed tomography follow‐up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions

One‐year clinical and computed tomography follow‐up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions

Clinical Outcomes of Successful Revascularization of Chronic Total Coronary Occlusions with Bioresorbable Vascular Scaffolds: A Systematic Review

Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis

Contact Info

Product

Resources

About